Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4567340 | 0.84 | CNR2 (0.44) | CNR1CNR2 | |
| SCHEMBL10653170 | 0.77 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL3693693 | 0.75 | CNR2 (0.45) | CNR1CNR2 | |
| SCHEMBL4570709 | 0.68 | HIF1A (0.43) | CNR1CNR2 | |
| SCHEMBL5425933 | 0.67 | CNR2 (0.57) | CNR1CNR2 | |
| SCHEMBL29627395 | 0.67 | CNR2 (0.45) | CNR1CNR2 | |
| SCHEMBL4825030 | 0.67 | CNR2 (0.40) | CNR1CNR2 | |
| SCHEMBL23802246 | 0.67 | CNR2 (0.50) | CNR1CNR2 | |
| SCHEMBL10655486 | 0.67 | BACE1 (0.40) | CNR1CNR2 | |
| SCHEMBL10655490 | 0.67 | BACE1 (0.40) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173867-B2 | Treatment of immune dysregulation using cannabinoid derivatives | IMMUGEN PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | TRAVIS CRAIG RICK (US) | 2012-05-17 | — | — | US | disclosed |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG R | 2008-05-08 | — | — | US | disclosed |
| US-20070179135-A1 | Cannabinoid derivatives | TRAVIS CRAIG R | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885 |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885 |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | CNR2, CNR1, ICOS | CNR1 2/4885CNR2 1/4885 |
| US-20070179135-A1 | Cannabinoid derivatives | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885 |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | CNR1, CNR2, ICOS | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.